中文摘要：
白斑病（Vitiligo）是一種由皮膚黑素細胞缺失引起的自身免疫性皮膚病。雖然光療和T細胞抑制療法已被廣泛用于誘導表皮色素再生，但由于人們對這一過程的細胞和分子調控機制理解不足，很少能實現色素恢復。本研究發現，雌雄小鼠黑色素干細胞（McSC）的表皮遷移速率存在顯著差異，這種差異源于紫外線B照射引發的性別二態性皮膚炎癥反應。通過使用基因工程小鼠模型及無偏倚的批量mRNA測序與單細胞mRNA測序技術，我們證實通過調控環氧合酶及其下游前列腺素產物的炎癥反應，可以有效調節紫外線B暴露下黑色素干細胞的增殖和表皮遷移。進一步研究表明，通過聯合調控巨噬細胞和T細胞（即先天免疫和適應性免疫）的療法可顯著促進表皮黑素細胞再生。基于這些發現，我們提出了一種針對Vitiligo等色素脫失性疾病患者的新型復色治療策略。
英文摘要：
Vitiligo is an autoimmune skin disease caused by cutaneous melanocyte loss. Although phototherapy and T cell suppression therapy have been widely used to induce epidermal re-pigmentation, full pigmentation recovery is rarely achieved due to our poor understanding of the cellular and molecular mechanisms governing this process. Here, we identify unique melanocyte stem cell (McSC) epidermal migration rates between male and female mice, which is due to sexually dimorphic cutaneous inflammatory responses generated by ultra-violet B exposure. Using genetically engineered mouse models, and unbiased bulk and single-cell mRNA sequencing approaches, we determine that manipulating the inflammatory response through cyclooxygenase and its downstream prostaglandin product regulates McSC proliferation and epidermal migration in response to UVB exposure. Furthermore, we demonstrate that a combinational therapy that manipulates both macrophages and T cells (or innate and adaptive immunity) significantly promotes epidermal melanocyte re-population. With these findings, we propose a novel therapeutic strategy for repigmentation in patients with depigmentation conditions such as vitiligo.
論文信息：
論文題目：Sexual dimorphism in melanocyte stem cell behavior reveals combinational therapeutic strategies for
cutaneous repigmentation
期刊名稱：Nature Communications
時間期卷：15, Article number: 796 (2024)
在線時間：2024年1月27日
DOI：doi.org/10.1038/s41467-024-45034-3
產品信息：
貨號：CP-005-005
規格：5ml+5ml
品牌：Liposoma
產地：荷蘭
名稱：Clodronate Liposomes and Control Liposomes
辦事處：Target Technology（靶點科技）
白斑病是由于皮膚黑素細胞被破壞，引發皮膚黑色素缺乏，形成局部白斑的疾病。其病因可能與自身免疫系統疾病、遺傳、神經化學物質等因素有關，不同年齡、性別和種族的人都可能患病。皮膚色素障礙疾病種類繁多。白斑病作為一種典型的自身免疫性疾病，全球發病率達0.5%-2%，其特征表現為表皮黑素細胞缺失導致的色素脫失斑塊。
白斑病發病機制涉及遺傳易感性、氧化應激、先天/適應性免疫異常及環境刺激等多重因素，這些因素共同導致CD8?T細胞異常活化，最終引發表皮黑素細胞破壞。因此，針對T細胞的靶向治療成為研究焦點。近期FDA批準的多種JAK抑制劑通過抑制CD8?T細胞募集，在改善白斑病患者復色方面顯示出療效。盡管II/III期臨床試驗證實這些療法可顯著改善皮膚色素沉著，但患者應答存在個體差異，且鮮有實現持久的色素再生。
氯膦酸鹽二鈉脂質體清除單核巨噬細胞，在白斑病模型中單核巨噬細胞功能研究，荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes見刊于Nature Communications：
Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體的材料和方法：
Clodronate liposome treatment
Mice were given doxycycline in water and the first dose of clodronate liposomes (CL) or PBS liposomes (PL) (Liposoma, Cat#CP-005-005) on the day prior to the first UVB irradiation. Male and female mice were given 250?µl and 200?µl CL/PL, respectively, due to weight differences. From one day after the first UVB, mice were given CL/PL daily until the collection day or 2 days following the third UVB. Mice for McSC translocation analysis were collected seven days following the third UVB irradiation.
